- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04096365
Subcostal Temporary Extracardiac Pacing Study (STEP)
Subcostal Temporary Extracardiac Pacing Study: Clinical Study of the AtaCor Extracardiac Pacing System
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Asunción, Paraguay
- Sanatorio Italiano
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Indicated for closed-chest cardiac invasive procedure with the potential for intra-procedural or post-procedural bradycardia and willing to be hospitalized for a minimum of 2 days post procedure.
Examples of such procedures include: transfemoral transcatheter aortic valve replacement (TAVR), balloon valvuloplasty, permanent pacemaker implantation and pacing lead extractions/revisions.
- Physically and mentally capable of providing informed consent.
- At least 18 years of age or of legal age to provide consent as required by local and national requirements.
Exclusion Criteria:
- Contraindicated or clinically unsuitable for transvenous lead placement;
- Implanted with an implantable cardioverter defibrillator (ICD) or transvenous defibrillation lead at the time of enrollment;
- History of a prior sternotomy (median or partial);
- History of prior surgery with disruption of the lung, pericardium or connective tissue between the sternum and pericardium;
- History of significant anatomic derangement of the thorax (e.g., pectus excavatum), prior chest radiation therapy or other reasons which may cause pericardial adhesions or complicate the AtaCor Temporary Pacing System insertion procedure;
- History of pericardial disease, pericarditis or mediastinitis;
- History of chronic obstructive pulmonary disease (COPD);
- NYHA functional classification IV at the time of enrollment;
- History of congenital heart disease;
- Patients with circumstances that prevent data collection or follow-up, including conditions that prevent ambulation and testing in multiple postures;
- BMI ≥ 35 kg/m2;
- History of allergies to any study device components;
- Pregnant or lactating (current or anticipated during study follow up); and
- Participation in any concurrent study without prior, written approval from the Sponsor.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Subcostal temporary extracardiac pacing lead
All subjects will receive a subcostal temporary extracardiac pacing lead for a minimum of 48 hours in-hospital and undergo all protocol testing.
|
The StealthTrac Lead is designed to facilitate extracardiac temporary ventricular pacing and sensing.
The distal end of the StealthTrac Lead is designed to reside within the connective tissue of the anterior mediastinum outside the pericardium.
The StealthTrac Lead is delivered using the MACH I Delivery Tool, which is designed to facilitate insertion of the StealthTrac Lead through a small skin incision parallel to the sternum, without the need for fluoroscopic guidance.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety Outcome: Number of Subjects Experiencing an Adverse Device Effect
Time Frame: 30 days
|
Safety will be evaluated through analysis of all Adverse Device Effects
|
30 days
|
Performance Outcome: Mean Pacing Capture Threshold (V)
Time Frame: Up to 2 days post insertion
|
Minimum current required to pacing the heart (in multiple postures)
|
Up to 2 days post insertion
|
Performance Outcome: Mean Pacing Impedance (Ohms)
Time Frame: Up to 2 days post insertion
|
Impedance measured while pacing the heart (in multiple postures)
|
Up to 2 days post insertion
|
Performance Outcome: Mean R-Wave Amplitude (mV)
Time Frame: Up to 2 days post insertion
|
R-Wave amplitudes measured while sensing the heart (in multiple postures)
|
Up to 2 days post insertion
|
Performance Outcome: % of R-R Intervals With Appropriate Pacing and Sensing During Activity
Time Frame: Up to 2 days post insertion
|
ECG Holter Recordings obtained during periods of rest and in-hospital activity.
The % of R-R intervals with appropriate pacing is calculated as the number of paced intervals that demonstrate pacing capture / the total number of pacing intervals.
The % of R-R intervals with appropriate sensing is calculated as the number of intervals where pacing is appropriately delivered or inhibited (depending on the programmed settings of the pacemaker) / the total number of R-R intervals.
The outcomes are presented a % of intervals and not an average of the percentages observed across patients.
|
Up to 2 days post insertion
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Paced QRS Duration (ms)
Time Frame: 1 day after insertion
|
QRS duration measured from 12-Lead ECG
|
1 day after insertion
|
Echocardiographic Assessment of Left Ventricular Stroke Volume During Pacing (mL)
Time Frame: 2 days after insertion
|
Measures of cardiac function obtained from echocardiography
|
2 days after insertion
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Martin Burke, D.O., AtaCor Medical
- Principal Investigator: Adrian Ebner, M.D., Sanatorio Italiano
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- DOC-10052
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Conduction Defect
-
AtaCor Medical, Inc.Recruiting
-
AtaCor Medical, Inc.RecruitingConduction DefectCroatia, Czechia
-
AtaCor Medical, Inc.Completed
-
AtaCor Medical, Inc.CompletedConduction DefectNew Zealand, Paraguay, Czechia
-
AtaCor Medical, Inc.Completed
-
Nantes University HospitalRecruitingCongenital Complete Heart Block | Cardiac Conduction Defect ProgressiveFrance
-
Assiut UniversityUnknown
-
Maastricht University Medical CenterActive, not recruitingHeart Diseases | Cardiac Conduction DefectNetherlands
-
Imperial College LondonCompletedLeft Bundle-Branch Block | Right Bundle-Branch Block | Non-Specific Intraventricular Conduction DefectUnited Kingdom
-
Imperial College LondonCompletedHeart Failure | Left Bundle-Branch Block | Left Ventricular Systolic Dysfunction | Right Bundle-Branch Block | Non-Specific Intraventricular Conduction DefectUnited Kingdom
Clinical Trials on Subcostal Temporary Extracardiac Pacing Lead
-
The First Affiliated Hospital with Nanjing Medical...Jiangsu Province Hospital of Traditional Chinese Medicine; Xuzhou Medical University and other collaboratorsUnknown
-
AtaCor Medical, Inc.Completed
-
Swift Sync, Inc.Regulatory and Quality SolutionsCompletedHeart Block | Valve Heart DiseaseParaguay
-
University of California, San FranciscoRecruitingRight Ventricular Dysfunction | Pulmonary Artery HypertensionUnited States
-
Guidant CorporationCompletedAcute Myocardial InfarctionNetherlands
-
Region SkaneSuspendedHeart Failure, Systolic | Left Bundle Branch Block | Wide QRS ComplexSweden
-
Hunan Provincial People's HospitalRecruitingTachyarrhythmia | Brady-tachy Syndrome | Bradyarrhythmia | Bradycardia; Syncope | AVB - Atrioventricular Block | Tachycardia BradycardiaChina
-
National University Hospital, SingaporeRecruitingPacemaker DDDSingapore
-
Catharina Ziekenhuis EindhovenWithdrawnHeart FailureNetherlands